Vis enkel innførsel

dc.contributor.authorPope, Marita K
dc.contributor.authorAtar, Dan
dc.contributor.authorSvilaas, Arne B
dc.contributor.authorHole, Torstein
dc.contributor.authorNielsen, Jørn Dalsgaard
dc.contributor.authorHintze, Ulrik
dc.contributor.authorCrisby, Milita
dc.contributor.authorRaatikainen, Pekka
dc.contributor.authorAiraksinen, K.E. Juhani
dc.contributor.authorVirdone, Saverio
dc.contributor.authorPieper, Karen
dc.contributor.authorKayani, Gloria
dc.contributor.authorLe Heuzey, Jean-Yves
dc.contributor.authorSteffel, Jan
dc.contributor.authorStepinska, Janina
dc.contributor.authorBassand, Jean-Pierre
dc.contributor.authorCamm, A. John
dc.identifier.citationAnnals of Medicine. 2021, 53 (1), 485-494.en_US
dc.description.abstractAims The objective was to evaluate the clinical characteristics, management and two-year outcomes of patients with newly diagnosed non-valvular atrial fibrillation at risk for stroke in Nordic countries. Methods We examined the baseline characteristics, antithrombotic treatment, and two-year clinical outcomes of patients from four Nordic countries. Results A total of 52,080 patients were enrolled in the GARFIELD-AF. Out of 29,908 European patients, 2,396 were recruited from Nordic countries. The use of oral anticoagulants, alone or in combination with antiplatelet (AP), was higher in Nordic patients in all CHA2DS2-VASc categories: 0–1 (72.8% vs 60.3%), 2–3 (78.7% vs 72.9%) and ≥4 (79.2% vs 74.1%). In Nordic patients, NOAC ± AP was more frequently prescribed (32.0% vs 27.7%) and AP monotherapy was less often prescribed (10.4% vs 18.2%) when compared with Non-Nordic European patients. The rates (per 100 patient years) of all-cause mortality and non-haemorrhagic stroke/systemic embolism (SE) were similar in Nordic and Non-Nordic European patients [3.63 (3.11–4.23) vs 4.08 (3.91–4.26), p value = .147] and [0.98 (0.73–1.32) vs 1.02 (0.93–1.11), p value = .819], while major bleeding was significantly higher [1.66 (1.32–2.09) vs 1.01 (0.93–1.10), p value < .001]. Conclusion Nordic patients had significantly higher major bleeding than Non-Nordic-European patients. In contrast, rates of all-cause mortality and non-haemorrhagic stroke/SE were comparable.en_US
dc.publisherInforma UK Limiteden_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.titleRisk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation–results from the GARFIELD-AF registryen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.source.journalAnnals of Medicineen_US
dc.description.localcode© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal